Evidence map›Paper›PMID 32726968›Full record

ReviewBiomolecules2020

More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Paulina Pecyna, Joanna Wargula, Marek Murias, Malgorzata Kucinska

Abstract readReview
In one paragraph

Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Bromo Analogues of Active 3,4,5,4'-Tetramethoxy-Molecules (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Stilbene Glycosides inPlants (Basel, Switzerland) · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paulina PecynaDepartment of Genetics and Pharmaceutical Microbiology, University of Medical Sciences, Swiecickiego 4 Street, 60-781 Poznan, Poland.
Joanna WargulaDepartment of Organic Chemistry, University of Medical Sciences, Grunwaldzka 6 Street, 60-780 Poznan, Poland.ORCID 0000-0002-7517-5345
Marek MuriasDepartment of Toxicology, University of Medical Sciences, Dojazd 30 Street, 60-631 Poznan, Poland.ORCID 0000-0002-2903-4912
Malgorzata KucinskaDepartment of Toxicology, University of Medical Sciences, Dojazd 30 Street, 60-631 Poznan, Poland.

Funding

Polish National Science Center UMO-2011/01/B/NZ4/03499
6 · The paper itself

Abstract

The concept of a scaffold concerns many aspects at different steps on the drug development path. In medicinal chemistry, the choice of relevant "drug-likeness" scaffold is a starting point for the design of the structure dedicated to specific molecular targets. For many years, the chemical uniqueness of the stilbene structure has inspired scientists from different fields such as chemistry, biology, pharmacy, and medicine. In this review, we present the outstanding potential of the stilbene-based derivatives. Naturally occurring stilbenes, together with powerful synthetic chemistry possibilities, may offer an excellent approach for discovering new structures and identifying their therapeutic targets. With the development of scientific tools, sophisticated equipment, and a better understanding of the disease pathogenesis at the molecular level, the stilbene scaffold has moved innovation in science. This paper mainly focuses on the stilbene-based compounds beyond resveratrol, which are particularly attractive due to their biological activity. Given the "fresh outlook" about different stilbene-based compounds starting from stilbenoids with particular regard to isorhapontigenin and methoxy- and hydroxyl- analogues, the update about the combretastatins, and the very often overlooked and underestimated benzanilide analogues, we present a new story about this remarkable structure.

Indexed as

AnimalsBibenzylsDrug DiscoveryHumansResveratrolStilbenesBibenzylscombretastatinisorhapontigeninResveratrolStilbenesbenzanilide derivativescombretastatinDMU-212isorhapontigeninpinosylvinstilbene analoguesthiobenzanilides

Identifiers

PMID32726968
PMCPMC7465418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.